|
|
||||||||
J Thorac Cardiovasc Surg 2008;136:1054-1060
© 2008 The American Association for Thoracic Surgery
Cardiopulmonary Support and Physiology |
a Cardiocenter, Department of Cardiac Surgery, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
b Cardiocenter, Department of Cardiology, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
c Department of Clinical Hematology, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
Received for publication October 20, 2007; revisions received February 13, 2008; accepted for publication March 7, 2008. * Address for reprints: Frantisek Bednar, MD, PhD, Cardiocenter, Department of Cardiac Surgery, Na Homolce Hospital, Roentgenova 2, 150 30 Praha 5, Czech Republic. (Email: fandabednar{at}email.cz).
| Abstract |
|---|
|
|
|---|
Methods: Eighty patients were enrolled in a prospective randomized study. Platelet activity was determined based on membrane expression of antigen CD62P (P-selectin) by means of flow cytometric analysis. Aspirin efficacy was assessed by using arachidonic acid–induced platelet aggregation. Blood samples were collected before the operation, immediately postoperatively, and on days 1, 2, 5, and 30.
Results: In the off-pump group expression of P-selectin was markedly increased in comparison with preoperative values, with a maximum difference observed on day 2 (+53%, P = .02), and it was significantly higher compared with that seen in the on-pump group on days 2 and 5 (+53% vs +4%, P = .004, and +20% vs –16%, P = .005). On day 30, P-selectin expression was similar both between the groups and in comparison with the preoperative values. Arachidonic acid–induced platelet aggregation was gradually decreasing until day 30, but on day 2, there was an unexpected increase in aggregation that was more expressed in the off-pump group.
Conclusions: The platelet activity is higher in the early postoperative period in off-pump compared with on-pump coronary artery bypass grafting. The present aspirin strategy seems to be insufficient in the early postoperative period, irrespective of the surgical technique used.
| Introduction |
|---|
|
|
|---|
Off-pump CABG surgery has been established as a less-invasive alternative to conventional CABG. Elimination of CPB leads to the reduction of hemostatic defects and consequently to less postoperative bleeding and fewer requirements for blood transfusion.3
However, several recent studies suggest that off-pump surgery could cause a procoagulant state, which appears within the first postoperative days and could possibly contribute to early thrombotic complications and affect early venous graft patency after off-pump CABG.4-7
Nevertheless, the described coagulation changes are often limited only to plasma markers, and not much is known about platelets and their activity in the first postoperative days after bypass surgery.8-11
The significance of platelets early after CABG is also supported by the fact that platelets play a key role in the process of arterial thrombosis and also the fact that the inhibition of platelets by early administered aspirin has a clear benefit against graft thrombosis and affects saphenous vein graft patency.12
In spite of this, changes in early and late platelet activity between off-pump and on-pump CABG and aspirin efficacy after both types of surgical intervention have not been thoroughly studied.
In the present prospective, randomized PRAGUE 11–CABARET study, we evaluated the early and late postoperative platelet activity between on-pump and off-pump CABG and compared aspirin efficacy on inhibition of platelet aggregation early and late after both types of operation.
| Materials and Methods |
|---|
|
|
|---|
Anesthetic and Surgical Technique
Fast-track anesthesia and off-pump and on-pump operations were performed as described previously.13,14
Heparin and Protamine Management
In the on-pump group heparin was administered at an initial dose of 300 IU/kg to achieve an activated clotting time (ACT) of 480 seconds. ACT was monitored every 30 minutes, and an additional heparin bolus (5000 IU) was administered when ACT was less than 440 seconds.
In the off-pump group heparin was administered at an initial dose of 150 IU/kg to achieve an ACT of more than 250 seconds. On completion of all anastomoses, the heparin effect was reversed with protamine chloride. An empiric dose regimen of 300 mg (in the on-pump group) and 100 mg (in the off-pump group) was administered, and if required, additional protamine was added to achieve an ACT of less than 130 seconds at the end of the operation.
Perioperative and Postoperative Drug and Fluid Management
In the perioperative period no antifibrinolytics (eg, aprotinin and tranexamic acid) were used in either group. Crystalloid solutions and 5% albumin solution were administered during the procedure. A red blood cell transfusion was administered when hemoglobin decreased to less than 8.5 g/dL or hematocrit to less than 26%. In the postoperative period a transfusion of fresh frozen plasma was administered when chest drain bleeding increased to more than 150 mL/h or to more than 100 mL/h for 2 consecutive hours. The red blood cell transfusion was administered according to similar criteria mentioned above. The platelet transfusion concentrates could be administered in the postoperative period when chest drain bleeding increased to 200 mL/h for a consecutive 3 hours and platelet count was less than 60,000/mm3. No other prohemostatic agents were recommended according to the study protocol. Aspirin (200 mg) was readministered 12 hours after the procedure in both groups. No additional antiaggregation or anticoagulation drugs (nonsteroidal anti-inflammatory drugs or low-molecular-weight heparin) were recommended during the first 5 days after the operation, according to the study protocol.
Blood Sampling and Analyses
Blood samples were collected in the morning before the operation, immediately after the operation (after skin closure, when the ACT was <130 seconds), and on postoperative days 1, 2, 5, and 30 (days 1, 2, 5, and 30). At the same time points, the samples for routine coagulation tests and biochemical analyses were collected.
Assays for Platelet Activity and Aspirin Efficacy
Platelet activity was determined by changes in the expression of the platelet surface antigen CD62P (P-selectin) by using flow cytometry, and aspirin efficacy was determined by means of light transmission aggregometry after the addition of arachidonic acid (AA).15
At the time points described above, 10 mL of venous blood was drawn in 2 citrated (9NC sodium citrate 3.2%) vacutainers.
Flow cytometry
Platelet surface antigens were analyzed as described previously.16
The sample was stored for 2 hours at 37°C. Supernatant was collected and platelet count was adjusted to 100 x 109/L with homologous plasma and phosphate-buffered saline. Fifty microliters of prepared sample was added to 50 µL of the stabilizer Thrombofix (Immunotech, Beckman–Coulter Co). This mixture was incubated for 2 hours at 37°C. Twenty microliters of prepared stabilized platelets were stained with the appropriate volume of mAbs at saturating concentrations: CD62P–fluorescein isothiocyanate (FITC)/CD41–phycoerythrin (Immunotech), CD62P-FITC/CD42b (Immunotech), and isotype control IgG1-FITC/IgG1–phycoerythrin (Immunotech). Stained samples were incubated for 10 minutes at room temperature, and 0.5 mL phosphate-buffered saline was added and mixed. The flow cytometer was calibrated with CYTO-COMP Reagent Kit (Immunotech) and the CYTO-COMP Cell Kit (Immunotech). Analysis was performed on an EPICS XL flow cytometer (Beckman–Coulter, Inc). The gating strategy of platelets was based on forward and side scatter and on the presence of CD42b antigen. At least 10,000 platelets were analyzed in each measurement. CD62P expression was determined as a percentage of positive cells.
Aggregometry
Platelet-rich plasma (PRP) was prepared immediately after blood collection by means of centrifugation of 5 mL of anticoagulated blood at 150g for 10 minutes at room temperature. PRP was adjusted to a minimum platelet count of 150,000/µL. Platelet-poor plasma was obtained from the remaining sample by means of centrifugation at 2500g for 20 minutes. Samples were assayed on a PAP-4 Platelet Aggregation Profiler (BioBata Corp) with platelet-poor plasma as 100% of transmittance. The transmittance was set to 0% after adding 200 µL of PRP. AA was added to each tube (the final concentration of AA in the PRP was 0.5 mg/mL), and the aggregation profiles were plotted (percentage transmittance vs time). Platelet aggregability was calculated as total aggregation (percentage at 5 minutes).17
Test reliability
The intra-assay coefficient of variation was 3.2% ± 2.4% for AA aggregability and 3.8% ± 4.1% for CD62P. The interassay (ie, intraindividual) variability was 8.9% ± 10.2% for AA and 6.9% ± 8.9% for CD62P in healthy non–aspirin-taking individuals.
Power Calculation
We were unaware of previous data comparing the difference in CD62P platelet membrane expression in patients after off-pump and on-pump CABG surgery. Thus we based our power calculations on the previous studies of comparing CD62P or other parameters of platelet activity in patients after percutaneous coronary intervention. We hypothesized a difference of two thirds of the standard deviation in logged data. Therefore we needed data from a minimum of 34 patients in each group for a P value of less than .05 and a 1-β value of greater than 0.8.
Statistical Analyses
Continuous variables were compared by using a 2-sample t test and categorical variables by using a
2 test for independence in contingency tables. The time courses of AA, CD62P, and platelets counts were analyzed by means of analysis of variance for repeated measures. Correlations were evaluated by using the Spearman test. The tests are carried out at the 5% significance level. The results are presented as means ± standard deviation or medians with 95% confidence intervals. Statistical analysis was performed with SPSS for Win v.14 (SPSS, Inc).
| Results |
|---|
|
|
|---|
|
|
The platelet counts before and after surgical intervention were similar and comparable in both groups (Figure 1 ). There was a trend toward a lower platelet count in the on-pump group (because of hemodilution), but there was no significant difference between groups. Platelet counts recovered to the preoperative values on day 5 and exceeded the preoperative values in both groups on day 30.
|
|
|
|
| Discussion |
|---|
|
|
|---|
In the available literature there are few and conflicting data concerning changes in platelet activity after cardiac surgery.8-11,18-21
Therefore the interpretation of our results is not easy. The activation of platelets could be related only to the process of healing and to the changes in hemostasis, which are usually present in the early postoperative period. Higher platelet activity in off-pump surgery can be a "normal" state in the postoperative process of hemostasis restitution after a major operation. In contrast, this condition could be impaired in on-pump surgery due to hemostasis dysfunction caused by an extracorporeal circuit and other factors (eg, oxygenator, cardioplegia solution, hypothermia, thrombin, heparin, and protamine). However, some recent studies have indicated that the changes in hemostasis in terms of its increase (procoagulant state) could really exist after off-pump surgery. For example, Lo and colleagues4
and Quigley and associates5
describe that in off-pump surgery the response of the coagulation system (platelets were not studied) increased in the later period after the operation (in 20 to 96 hours or in 72 hours) in comparison with that after on-pump surgery. It is not clear from the published studies whether platelets participate in this procoagulant state. Even though the role of platelets in this process has been questioned by some authors, with regard to the complexity of the hemostasis process, including interactions between the coagulation system of blood proteins and platelets, it is very probable that platelets take part in this process.18
According to our results, platelets could play an important role in this state. Very few studies can be found in the available literature that would provide a comparison with our results by means of their methodology. A recently published study by Ballotta and coworkers8
also described changes in platelet activity (P-selectin and Annexin-V) but only very early after surgical intervention (2 hours). Similar to our study, it recorded an increase in P-selectin expression in both groups in the early postoperative period, but this increase was significantly higher in on-pump surgery compared with off-pump surgery. No comparisons in the later postoperative period were described. Parolari and associates20
did not find any significant changes in P-selectin expression between off-pump and on-pump CABG on days 4, 8, and 30 after the operation, although they had a lower number of patients.
Higher platelet activity is associated with thrombotic complications in patients with coronary artery disease, and can be used to predict patients at risk of an adverse cardiovascular event (eg, reappearance of ischemia and the need for reintervention after percutaneous coronary intervention).22-24
It is not clear whether higher platelet activity can be associated with early bypass graft failure or whether it can contribute to negative clinical outcomes after bypass surgery.19
Although it is not possible to make a valid conclusion from the platelet tests performed in our 4 patients with a postoperative MI (our study was not designed for this objective), at least 2 of them had significantly higher preoperative values of P-selectin. However, according to Poston and coworkers,18
what could cause graft failure is not the platelet activation itself but its interaction with coagulation cascade reactions, which appear on the surface of activated platelets at the site of endothelial injury. Further studies are needed to clarify the complexity of these relations.
Apart from the assessment of platelet activity by means of P-selectin expression, we also focused on the evaluation of platelet aggregation after repeated administration of aspirin early after bypass surgery. It must be emphasized that P-selectin expression and platelet aggregation do not correlate together, which has been proved not only in our study but also in the available literature.25
Each of these factors describes something else in platelet function and activation. AA-induced platelet aggregation measured by means of light transmission aggregometry is today considered to be a reference method to evaluate aspirin efficacy, and its results provided very interesting findings.26
On postoperative day 2, after previous reduction in aggregability caused by heparin and CPB (in the on-pump group), platelet aggregation increased unexpectedly and even more in the off-pump group. The increase in aggregability was recorded despite the administration of 2 doses of aspirin. Thus we can assume that platelet function is restored, but the inhibition effect of aspirin is still insufficient. This condition is more expressed in less dysfunctional platelets in the off-pump group. Unfortunately, changes in platelet aggregation were not measured on postoperative days 3 and 4 according to the study protocol. Therefore the expected inhibition effect of aspirin occurs approximately between postoperative days 3 and 5. We can speculate whether the less dysfunctional platelets after off-pump surgery are, in contrast, more sensitive to the inhibition effect of aspirin in the later postoperative period, as the values of AA-induced platelet aggregation indicated on postoperative day 5. Insufficient platelet inhibition early after bypass surgery was also described by Zimmermann and colleagues,27
who measured levels of thromboxane B2 in plasma after oral administration of aspirin. Similarly, Poston and coworkers19
recorded a significant increase in platelet resistance to aspirin effect in off-pump patients with early graft thrombosis. Aspirin insufficiency (resistance) early after bypass surgery is therefore a real problem to which more attention must be paid. The clinical effect of all these findings is also supported by the fact that the early postoperative period is extremely risky for early graft failure because of thrombosis.28
There arises a question whether modification or intensification of the dose regimen of aspirin or different antiplatelet strategies after off-pump and on-pump bypass surgery could lead to a more effective inhibition of aggregation with a minimum influence on postoperative bleeding and thus possibly to better clinical outcomes. Our results also support considerations about dual therapy with aspirin and clopidogrel, when clopidogrel, unlike aspirin, inhibits not only platelet aggregability but also P-selectin expression.29
However, to answer these and other questions, we need additional studies.
Study Limitations
Our trial includes a low number of patients, and it will be necessary to confirm or disprove our findings in future studies in a larger number of patients with a possible use of other sensitive markers of platelet activity and methods of measurement of aspirin efficacy. Our patients form a group of selected patients because our objective was to compare the influence of 2 different operative methods on the defined markers of platelet activity. The authors are aware of the possibility of obtaining different results in acute patients whose platelet activity might have already been primarily affected. Also, by excluding the patients with postoperative MI, the authors do not ignore the intention-to-treat rule, but they try to prevent the distortion of results by those patients who might primarily show higher postoperative platelet activity as a consequence of MI. Furthermore, we have to take into account different doses of heparin/protamine in both types of operation and their possible influence on platelet dysfunction. A certain limitation to the interpretation of the results is also caused by the fact that antifibrinolytics were not used. However, a distortion of the results could be caused by using a different dose in the off-pump and on-pump groups. Also, the administration of a 200-mg dose of aspirin does not correspond with standard guidelines, but this dose is usual in the Czech Republic because 325 mg of aspirin is not registered in our country.
| Conclusions |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Afilalo, M. Rasti, S. M. Ohayon, A. Shimony, and M. J. Eisenberg Off-pump vs. on-pump coronary artery bypass surgery: an updated meta-analysis and meta-regression of randomized trials Eur. Heart J., October 10, 2011; (2011) ehr307v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Doi and H. Yaku Importance of cerebral artery risk evaluation before off-pump coronary artery bypass grafting to avoid perioperative stroke Eur J Cardiothorac Surg, November 1, 2010; 38(5): 568 - 572. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |